Additional file 1 of Neoadjuvant camrelizumab combined with metronomic chemotherapy in patients with advanced esophageal squamous cell carcinoma: a pilot randomized phase 2 trial

作者：Zhiming Chen, W. Li, Yumeng Guo, Yongjun Zhu, Yang Song, Jiayan Wu, Wanwei Zheng, Yujen Tseng, Lishuang Lin, Feng Tang, Beibei Mao, Peng Zhao, Xiangyu Guo, Shiman Fu, Gang Chen, Ning Wu, Bin Lv, Yao Liu, Shenyang Zhao, Shaocong Mo, Kewei Ma, Kaiyi Fu, Hongyang Zhang, George Zhang, Feifei Luo, Zhongguang Luo, Jianxing Liu · 发表于：Figshare · 年份：2026 · DOI：10.6084/m9.figshare.31969224 · 研究领域：Esophageal Cancer Research and Treatment、Cancer Immunotherapy and Biomarkers、Colorectal and Anal Carcinomas

Additional file 1: Additional Methods, Figures S1–S8 and Tables S1–S3. Fig S1- [Comprehensive Analysis of Treatment Outcomes]; Fig S2- [DFS and OS outcomes]; Fig S3- [Transcriptomic and pathway enrichment analyses of paired pre- and post-treatment resection specimens of both MCT and IO + MCT groups]; Fig S4- [Changes in the transcriptomic pattern of immune microenvironment before and after treatment in both MCT and IO + MCT groups]; Fig S5- [Bulk RNA-seq analysis and its correlation with pathological response in IO + MCT group]; FigS6- [Validation of CD39 signatures and pathological response in IO + MCT patients by DSP-WTA results]; FigS7- [Correlation between genomic features and pathological responses]; FigS8- [The comprehensive dotchart of pCR rates previously reported in other neoadjuvant treatment regimens for locally advanced resectable ESCC randomized or retrospective clinical studies]; FigS9- [Histopathological identification of tertiary lymphoid structuresin tumor tissue]; Tables S1-[Baseline demographic and clinical characteristics of the included patients]; Tables S2-[Pretreatment clinical stage and posttreatment pathological stage]; Tables S3- [Postoperative complications in patients underwent surgery].